Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Immune Modulation / Antimicrobial StackEvidence Grade: A (TA1) / B (LL-37)
Thymosin Alpha-1 + LL-37 Stack Protocol Guide
The Thymosin Alpha-1 + LL-37 stack is the most comprehensive immune support peptide protocol, combining adaptive immune modulation with innate antimicrobial defense. TA1 enhances T-cell maturation, NK cell activity, and dendritic cell function. LL-37 (Cathelicidin) is a human antimicrobial peptide that directly kills bacteria, viruses, and fungi while modulating innate immune responses and promoting wound healing. Together, TA1 optimizes adaptive immunity for pathogen recognition while LL-37 provides immediate broad-spectrum antimicrobial activity.
TA1 is the master regulator of adaptive immunity. It promotes T-cell maturation in the thymus, activates NK cells for innate surveillance, enhances dendritic cell antigen presentation, and modulates Toll-like receptors for pathogen recognition. It has been approved in over 30 countries for hepatitis B/C and as a cancer immunotherapy adjuvant, demonstrating its clinical effectiveness.
LL-37 Synergy
LL-37 is the only human cathelicidin, serving as the first line of innate antimicrobial defense. It directly disrupts bacterial, viral, and fungal membranes, neutralizes endotoxin (LPS), and activates innate immune cells. While TA1 coordinates the adaptive immune response (which takes days), LL-37 provides immediate antimicrobial coverage, ensuring comprehensive protection from first contact through coordinated elimination.
Combined Dosing Protocol
Protocol
Compound 1
Compound 2
Timing
Duration
Standard
TA1 1.6mg 2x/week
LL-37 100mcg daily 5x/week
TA1: Tu/Th, LL-37: M-F
8-12 weeks
Acute
TA1 1.6mg 3x/week
LL-37 200mcg daily
TA1: M/W/F, LL-37: daily
4-6 weeks
Maintenance
TA1 1.6mg 1x/week
LL-37 100mcg 3x/week
TA1: Mon, LL-37: M/W/F
Ongoing
Reconstitution & Preparation
Thymosin Alpha-1 Preparation
TA1 vial: 1.6mg or 3.2mg lyophilized
1.6mg vial: reconstitute with 1mL BAC water
Use entire vial per dose (1.6mg)
Refrigerate, use within 14 days
LL-37 Preparation
LL-37 vial: typically 5mg lyophilized
Reconstitute with 2mL BAC water = 2,500mcg/mL
100mcg dose = 4 units on insulin syringe
Refrigerate, use within 21 days
Stacking Schedule (AM/PM Timing)
AM Protocol
LL-37 days (M-F): 100mcg SubQ, abdomen
TA1 days (Tu/Th): 1.6mg SubQ, abdomen
Overlap days: inject both at different sites
Morning preferred for immune activation timing
PM Protocol
No PM injections for standard protocol
TA1 can alternatively be taken before bed
Immune function most active during sleep
Support with vitamin D, zinc, vitamin C
Expected Timeline
Week 1-2
TA1 begins T-cell and NK cell upregulation. LL-37 provides immediate antimicrobial coverage. Mild immune activation symptoms possible.
Week 3-4
Adaptive immune optimization measurable. LL-37 effects compounding. Reduced frequency of minor infections.
Week 5-8
Full immune synergy. Robust innate and adaptive responses. Significantly fewer illnesses, faster recovery.
Week 9-12
Mature immune remodeling. T-cell populations optimized. Transition to maintenance protocol.
Side Effects & Monitoring
Common Side Effects
Injection site redness (both, mild)
Flu-like symptoms first TA1 doses (immune activation)
Mild fatigue during first week
Headache (uncommon)
TA1 has extensive clinical safety data from hepatitis and cancer immunotherapy use.
Precautions
TA1 may temporarily flare autoimmune conditions
Immunosuppressive drug patients consult physician
LL-37 high doses may cause mast cell degranulation
Start at standard doses before increasing
Monitor for excessive immune activation
Blood Work Recommendations
Panel
Markers
Timing
Immune Panel
CD4/CD8 ratio, NK cell count, lymphocyte subsets
Baseline, Week 6, Week 12
Inflammatory
CRP, ESR, ferritin
Baseline, Week 4, Week 8
Vitamin D
25-OH vitamin D
Baseline
Basic
CBC with differential, CMP
Baseline, Week 6
CD4/CD8 normalization and NK cell increases are primary TA1 markers. CRP/ferritin track inflammation. Optimize vitamin D to 60-80 ng/mL.
